Paolo Forte

Paolo Forte

Auto-generated profile, based on publicly available information

Paolo Forte

Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Retina
Verified
Journal Article
Closed access
RSRiccardo Md Sacconi
Riccardo Md Sacconi
PFPaolo Forte
Paolo Forte
VCVittorio Capuano
Vittorio Capuano
Alexandra MiereAlexandra Miere
Alexandra Miere
ECEliana Costanzo
Eliana Costanzo
GQGiuseppe Querques
Giuseppe Querques
Purpose: To investigate fellow eyes of newly diagnosed unilateral exudative Type 3 (T3) macular neovascularization (MNV) patients by assessing the presence and progression of a preclinical neovascular component during a 3-year follow-up. Methods: This is a longitudinal study involving three retinal referral centers. Patients affected by unilateral exudative treatment-naive T3 MNV were enrolled. Results: Twenty-four eyes of 24 patients (79 ± 6 years old) were enrolled. Nine eyes (37%) displayed a nonexudative T3 MNV at baseline that developed exudation after a mean of 9 ± 9 months. Fifteen eyes that did not display a nonexudative Type 3 MNV at baseline. Five eyes (21%) did not display neovessels at baseline, but showed a nonexudative T3 after 13 ± 9 months, and exudation after 8 ± 3 months. Five eyes (21%) developed active exudative T3 MNV after 23 ± 9 months, with no detectable nonexudative stage at baseline. Five eyes (21%) did not show MNV, but progressed to geographic atrophy by 36 months of follow-up. Overall, T3 MNV in the fellow eye accounted for 79%, all developing exudation over 3 years of follow-up. Conclusion: The occurrence of a nonexudative T3 MNV is a frequent event in the fellow eye of patients newly diagnosed with unilateral exudative T3 MNV and it precedes the development of exudation over 3 years (prevalence of 37% and cumulative incidence of 79%). Optical coherence tomography angiography approach may be used to perform an early diagnosis and treatment of patients with T3 MNV.

20 October 2024 in Acta Ophthalmologica
Verified
Journal Article
Open access
PFPaolo Forte
Paolo Forte
JCJennifer Cattaneo
Jennifer Cattaneo
FPFelice Cardillo Piccolino
Felice Cardillo Piccolino
AAAlessandro Arrigo
Alessandro Arrigo
PCPaolo Corazza
Paolo Corazza
MNMassimo Nicolò
Massimo Nicolò
Purpose: To test the prognostic role of anterior scleral substantia propria (ASSP) thickness in predicting the 3‐month response after half‐dose photodynamic therapy (PDT) in central serous chorioretinopathy (CSCR) and to assess its clinical relevance of ASSP in different CSCR phenotypes.Methods: A prospective, exploratory, multi‐centre cohort study conducted at IRCCS San Martino Hospital (Genoa, Italy) and Jules‐Gonin Eye Hospital (Lausanne, Switzerland). Demographic and clinical data, and optical coherence tomography (OCT) were collected at baseline and 3 months after PDT. Based on OCT images, we categorized CSCR phenotypes and collected clinically relevant imaging metrics. ASSP thickness was obtained from four different measurements using anterior segment (AS) OCT. Multivariable regression models were performed to evaluate the distribution of ASSP thicknesses among different CSCR phenotypes and to test the prognostic role of ASSP thickness in discriminating between PDT responders (complete subretinal fluid reabsorption) and partial responders.Results: The study cohort comprised 109 Caucasian patients (82 males, 75.2%) with a total of 142 eyes: 84 eyes simple (59.1%) versus 58 eyes complex (40.9%) CSCR. A linear normal model confirmed a positive association between complex CSCR and higher ASSP thickness (β = 26.1, 95% CL = 12.1/40.1, p < 0.001), with a low prevalence of ciliochoroidal effusion loculations in AS‐OCT (1/142 eyes, 0.7%). ASSP thickening was positively linked to the presence of posterior cystoid retinal degeneration (PCRD; p = 0.002), indicating a potential role in the pathogenesis of severe CSCR phenotypes. In the subgroup of treated patients (61 eyes), 63.9% had a complete response after PDT. In these patients a logistic binary model highlighted a significantly higher risk of PDT non‐responsiveness (OR = 9.62, 95% CL = 2.44/37.9, p = 0.001) associated with a 60‐unit increase in ASSP thickness levels. By contrast, other anatomical parameters (i.e., body surface area, age, gender, axial length) showed no remarkable prognostic roles.Conclusion: This research highlighted the association of ASSP thickening with complex CSCR phenotype in Caucasian patients and its role in predicting PDT efficacy. These findings enhance our comprehension of the anatomical risk factors in patients affected with CSCR and potentially guide a better understanding of non‐responsive cases to PDT treatment.

31 March 2022 in European Journal of Ophthalmology
Verified
Journal Article
Open access
VCVittorio Capuano
Vittorio Capuano
PFPaolo Forte
Paolo Forte
RSRiccardo Sacconi
Riccardo Sacconi
Alexandra MiereAlexandra Miere
Alexandra Miere
CMCarl-Joe Mehanna
Carl-Joe Mehanna
GQGiuseppe Querques
Giuseppe Querques
Introduction: To report two cases of Acute Macular Neuroretinopathy (AMN) presented as the first stage of SARS-CoV-2 infection in two European countries during the third wave of pandemic viral infection in the early months of 2021. Observations: A unilateral case of type 1 AMN in a man and a bilateral case of type 2 AMN in an otherwise heathy patients were reported. Sudden onset of paracentral scotoma characterized the cases with no systemic symptoms. Structural optical coherence tomography (OCT) shows multifocal middle and inner retinal hyperreflective infarctions. OCT-Angiography showed the presence of hypoperfusion of the deep capillary plexus (DCP) corresponding to the hyperreflective lesions visible on structural OCT, confirming the diagnosis. Conclusions and importance: Type 1 and type 2 AMN may be the first stage of SARS-CoV-2 infection. We suggest testing all patients with AMN for SARS-CoV-2. In our cases, the natural history of AMN associated with SARS-CoV-2 infection was similar to already described cases of AMN.

15 January 2025 in Survey of Ophthalmology
Verified
Journal Article
Closed access
PFPaolo Forte
Paolo Forte
MPMichel Paques
Michel Paques
JCJennifer Cattaneo
Jennifer Cattaneo
BDBénédicte Dupas
Bénédicte Dupas
DCDaniela Castro-Farias
Daniela Castro-Farias
GQGiuseppe Querques
Giuseppe Querques

30 January 2024 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
PFPaolo Forte
Paolo Forte
VFVincenzo Fontana
Vincenzo Fontana
JMJulia Muzio
Julia Muzio
LCLuca Di Cello
Luca Di Cello
PCPaolo Corazza
Paolo Corazza
MNMassimo Nicolò
Massimo Nicolò
Aims To explore prognostic multimarker models for progression to macular fibrosis (MF) over 24 months specific to type 3 macular neovascularisation (T3 MNV). Methods This retrospective, exploratory, single-centre, cohort study comprised 65 eyes of 43 Caucasian patients with treatment naive T3 MNV, all with a 24-month follow-up post anti-VEGF therapy using a strict pro-re-nata (PRN) regimen. Data on demographic features, clinical findings, frequency of intravitreal treatments and optical coherence tomography biomarkers were collected at baseline and after 12 and 24 months of follow-up. Logistic regression models (LRM) and receiver-operating curve (C-index) analyses were performed to evaluate the prognostic ability of the studied biomarkers in discriminating between MF affected and unaffected patients. Results At final follow-up, MF was present in 46.2% of eyes. Subretinal hyper-reflective material (SHRM) and subretinal pigment epithelium multilaminar hyper-reflectivity (multilaminae) emerged as significant predictors for MF, with adjusted odds ratios (OR) of 18.0 (95% CL 13.4 to 24.1) and 11.8 (95% CL 8.66 to 16.0), respectively. Additionally, the presence of multifocal lesions (OR 0.04, 95% CL 0.01 to 0.30) appeared to decrease the likelihood of MF. C-indexes for the selected LRMs ranged between 0.92 and 0.88, indicating a comparably high discriminant ability. Despite consistent treatment schedules between the two groups (MF: median intravitreal treatment (IVT) number=10.5, IQR=7; non-MF: median IVT=10, IQR=6), a decline in best-corrected visual acuity was noted in the group with MF onset over the 24-month follow-up (−13.0 ETDRS letters; 95% CL –22.1 to –3.9; p=0.006). Conclusion Our study identifies SHRM and multilaminae as relevant predictors of 24-month onset of MF in patients with T3 MNV. These findings enrich our understanding of the development of MF in T3 MNV and can guide improved risk prognostication. Future research should consider larger samples and prospective designs to validate these predictors.

7 February 2026 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
PFPaolo Forte
Paolo Forte
Lorenzo Ferro DesideriLorenzo Ferro Desideri
Lorenzo Ferro Desideri
MNMarco Nassisi
Marco Nassisi
FMFederica Milanesi
Federica Milanesi
AFAlessandro Feo
Alessandro Feo
MNMassimo Nicolò
Massimo Nicolò
Aims: To investigate the influence of macular drusen phenotypes on dark adaptation (DA) in intermediate age-related macular degeneration (iAMD). Methods: This cross-sectional, multicentric study enrolled 57 eyes of 43 iAMD patients. Drusen were subclassified as cuticular, soft, reticular pseudodrusen (RPD), or combined soft + RPD based on multimodal imaging. Dark adaptometry (AdaptDx; 20-minute test-time) assessed DA function through rod intercept time (RIT), last measured log sensitivity (LMLS; primary outcome) and area under the DA curve (AUDAC; secondary outcome). OCT volumes (30°x20° field) were analyzed using an AI-enhanced algorithm providing a quantification of chorioretinal layers and pigment epithelium detachments (PED) volumes. Multivariable tobit and linear regression analyzed associations between drusen phenotypes and DA outcomes. Results: Drusen phenotype distribution was: cuticular 13 eyes (22.8%), soft 13 eyes (22.8%), isolated RPD 21 eyes (36.8%), and combined soft + RPD 10 eyes (17.5%). Nearly all eyes reaching RIT within the 20-minute test ceiling (10 of 11 eyes) had cuticular drusen, which showed preserved rod function (LMLS: 2.9 ± 0.2 log-units; AUDAC: 10.3 ± 3.2 log-units·min; RIT: 14.9 ± 4.5 min) despite presenting the highest PED volumes (301 ± 152 nL). Conversely, isolated RPD demonstrated most severe dysfunction (LMLS: 1.7 ± 0.3; AUDAC: 23.7 ± 5.39). Soft drusen showed intermediate impairment (LMLS: 2.2 ± 0.2; AUDAC: 18.4 ± 2.4). Drusen phenotype was the most significant predictor of DA outcomes in both regression models (p < 0.001). Conclusion: Dark adaptometry reveals distinct patterns of DA impairment across drusen phenotypes, necessitating precise drusen classification when dark adaptometry serves as a functional endpoint in iAMD clinical trials. Future studies should employ extended test protocols (40-minute ceiling) to confirm these findings. Clinical trial number: Not applicable.